GlassScriptPhysician profile
Ahana Sen
NPI 1679936058
$5,812.12
in general payments reported to CMS, 2019-2025
29 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $1,951 · 2023: $1,340 · 2024: $1,499 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.07 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.13 | 2022-2025 | Rinvoq, Creon, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $612.37 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $569.08 | 2021-2025 | Tremfya, Stelara |
| Apollo Endosurgery US INC | $364.72 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Conmed Corporation | $263.09 | 2022-2024 | Conmed Biliary |
| Boston Scientific Corporation | $254.02 | 2021-2024 | Orise |
| Janssen Scientific Affairs, LLC | $212.49 | 2021-2023 | Stelara, Remicade |
| Ironwood Pharmaceuticals, INC | $191.85 | 2023-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.53 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $170.78 | 2022 | |
| Genzyme Corporation | $152.01 | 2023-2025 | |
| Medtronic, INC. | $146.63 | 2023-2025 | Manoscan, Endoflip, Bravo |
| E.R. Squibb & Sons, L.L.C. | $138.83 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $136.78 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $121.49 | 2022-2023 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $116.87 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $79.23 | 2023 | Dificid |
| Lilly USA, LLC | $68.24 | 2024 | Omvoh |
| Cook Medical LLC | $66.89 | 2024 | Echotip Insight, Instinct |
| Merit Medical Systems INC | $57.25 | 2024 | Elation Balloon Dilator |
| Qol Medical, LLC | $51.47 | 2022-2023 | Sucraid |
| Ardelyx, INC. | $47.25 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $45.90 | 2024-2025 | Zenpep |
| Celgene Corporation | $34.57 | 2023-2024 | Zeposia |
| Evoke Pharma, INC. | $34.28 | 2024 | |
| Braintree Laboratories, INC. | $25.93 | 2023 | Suflave, Sutab |
| Alcresta Therapeutics, INC. | $25.00 | 2022 | |
| Madrigal Pharmaceuticals | $21.77 | 2025 | Rezdiffra |
| Pfizer INC. | $14.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahana Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.